Understanding and Targeting Extramedullary Acute Leukemia
Official title: Understanding and Therapeutic Targeting of Extramedullary Acute Leukemia
Funded at New York University School of Medicine · NIH-11391429 · Data updated 2026-11-12
A clinician-research team is studying myeloid sarcoma, a form of AML that forms solid tumors outside the bone marrow, to develop new treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 22, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $716,681 |
| NIH project number | 1R01CA305969-01A1 |
| Project ID | NIH-11391429 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients diagnosed with extramedullary AML/myeloid sarcoma and matched AML patients whose samples are available for analysis.
✕Less likely to help
Patients not eligible for sample collection or not meeting the site’s inclusion criteria may not benefit from this research.
What this research studies
Myeloid sarcoma is a challenging AML subtype with poor survival, and current chemotherapy is often ineffective. The project uses advanced genomic, transcriptomic, and spatial mapping on patient samples from diagnosis and various body sites to understand how these tumors evolve outside the marrow. By comparing extramedullary tumors with matched bone marrow and other sites, researchers aim to identify unique mutations and pathway activations that could be targeted with new therapies. This work could pave the way for personalized treatments for patients facing extramedullary disease.
Why it matters
Potential benefit: If successful, the study could lead to targeted therapies that improve survival and outcomes for people with extramedullary AML.
How similar studies have gone: Previous studies have shown that integrating genomic and transcriptomic data can reveal actionable targets in AML, though extramedullary disease remains a high-need area.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Aifantis, Iannis — New York University School of Medicine
- Study coordinator: Aifantis, Iannis
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Reducing leukemia disparities in Latino children and teens
A large, multi-project effort aims to understand why Latino children with acute lymphoblastic leukemia have worse outcomes and how to reduce those gaps.
-
Genomic advances to improve outcomes in high-risk acute leukemia
A physician-scientist team is studying the genetic drivers of pediatric acute leukemia to find new ways to diagnose and treat it, with the goal of improving cure rates for kids.
-
Diversifying acute leukemia trial enrollment through multilevel approach
Aiming to broaden participation in acute leukemia trials by testing a multi-layer plan that addresses barriers for adults with AML.
-
Blocking menin to treat acute leukemias with high HOX gene activity
This work develops new drugs that block a protein called menin to help people with certain aggressive acute leukemias driven by HOX gene activation.
-
Predicting methotrexate-related brain side effects in children with ALL
This project works to predict which children and teens with acute lymphoblastic leukemia will develop methotrexate-related neurotoxicity using clinical signs and biological data.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.